Currently, there are no approved treatments for CMT1A disease though there have been considerable interest in the potential of ascorbic acid (AA) as a therapy leading to six clinical trials investigating the efficacy of AA on CMT1A [6–11]. This evidence concerns the gene PMP22 and Charcot-Marie-Tooth disease type 1A.